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Abstract
Background: The GP5+/GP6+ PCR assay is a well-established HPV detection technique. This study has examined the effects
of incorporating 'hot start' and 'touchdown' steps into the protocol. In addition, dTTP was substituted with dUTP to permit
contamination control measures against carry-over PCR product.
Methods: Firstly, HPV-16 was amplified from SiHa cell DNA (0.1 ng–100 ng) diluted in a background of C-33A DNA (100 ng-
2 µg). Secondly, the detection of small quantities (15ag-1.5pg) of HPV recombinant plasmids (types 16, 31, 33, 45, 51, 52, and
56) diluted in C-33A DNA was investigated. Thirdly, clinical sample DNA extracts (cervical smears, formalin-fixed vaginal lesions
and breast tumors) were tested for HPV. Six different PCR protocols were assessed. HPV was detected by gel electrophoresis,
and by Southern and dot blot hybridization.
Results: HPV detection sensitivity was dependent on the total amount of DNA in a PCR. Touchdown protocols supported
HPV-16 detection from 1 ng or 0.5 ng SiHa cell DNA in a background of 2 µg or 1 µg C-33A DNA respectively, and from 0.1
ng of SiHa cell DNA (~28 copies HPV-16) in 500 ng or 100 ng background DNA. Under standard GP5+/GP6+ annealing
conditions, HPV-16 went undetected when the DNA content of a PCR was 2 µg or 1 µg, and with 500 ng C-33A DNA the
sensitivity limit was 1 ng SiHa cell DNA. HPV recombinant plasmids were each detected with high (albeit varying) sensitivity by
a touchdown protocol. HPV-31 was better amplified under standard annealing conditions (1.5fg in 100 ng background DNA)
than by a touchdown approach (15fg detection limit). HPV-52 was not amplified by the standard protocol at the dilutions tested.
Seventeen different HPV types were demonstrated in 47/65 (72%) abnormal cytology samples recorded as HPV negative by
standard GP5+/GP6+ conditions. Twenty-one different HPV types were recorded in 111/114 (97%) vaginal lesions. Multiple
infections were also detectable using a touchdown approach. Of 26 breast tumors, 5 (19%) tested HPV positive by the standard
assay and 15/26 (58%) using a touchdown protocol.
Conclusion: Touchdown modification of the GP5+/GP6+ PCR assay enables the detection of HPV undetected under regular
assay conditions. The use of standardized DNA quantities in a PCR rather than standard sample volumes containing arbitrary
amounts of DNA is supported. A touchdown approach may be beneficial as an analytical test for the re-evaluation of (apparently)
HPV negative abnormal cervical cytological or histological samples, and for investigating the association of HPV with disease
conditions at diverse organ sites. The clinical utility of a touchdown approach for HPV detection requires further investigation
as increased assay analytical sensitivity may not necessarily equate with improved clinical sensitivity or specificity.
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Background
The association of human papillomaviruses (HPV) with
invasive cervical carcinoma and its precursor lesions is
well characterized [1,2]. There is also an emerging body of
data indicating that HPV may contribute to tumor etiol-
ogy at a variety of other anatomical sites [3]. For example,
high-risk HPV types have been detected in up to 48% of
breast carcinomas [4], although other studies have
reported an absence of HPV in these tumors [5].
Clearly, any estimate of HPV prevalence amongst a tissue
sample set is dependent on the detection method used.
Commonly employed PCR based assays include the Gen-
eral Primer Mediated 5+/6+ (GP5+/GP6+) [6,7] and the
MY09/MY11 [8] systems that amplify sequences from the
L1 region of the HPV genome. Since the early/mid-90 s,
when these assays were first developed a number of mod-
ifications that can improve PCR efficiency have been
described. In addition, there have been improvements in
thermal cycler specifications. This study has examined the
effects of incorporating 'hot start' [9] and 'touchdown'
[10] steps into the GP5+/GP6+ assay. Assays have been
tested for use with dUTP instead of dTTP so that a uracil
N-glycosylase (UNG) pre-PCR-incubation step can be
included to degrade any contaminating carry-over PCR
product present at reaction set up. The effect of the quan-
tity of background DNA in an individual PCR on the lim-
its of HPV detection has been specially investigated.
Protocols have been tested on HPV recombinant plas-
mids, and DNA extracted from cervical cell lines, cervical
cytology samples, and from formalin-fixed, paraffin-
embedded (FFPE) vaginal intraepithelial neoplasia
(VAIN) lesions and breast invasive ductal carcinomas
(IDC).
Methods
Materials
All patient materials used in this study were obtained and
analyzed with Institutional Review Board approval.
Cell lines
SiHa cells that contain one copy of the HPV-16 genome
integrated at chromosome 13q21-31 [11], and C-33A
cells derived from an HPV negative cervical carcinoma,
were acquired from the American Tissue Culture Collec-
tion (ATCC), Manassas, VA.
HPV recombinant plasmids
HPV types 16, 45, and 51 were received courtesy of Dr. E-
M de Villiers, Deutsches Krebsforschungszentrum (dkfz),
Heidelberg, Germany. HPV-33 was received courtesy of
Dr. Gerard Orth, Institut Pasteur, Paris, France. HPV-31,
52, and 56 were obtained from the ATCC.
Cervical cytology samples
Remnant cells (following cervical smear testing) were
obtained from samples diagnosed as low-grade cervical
squamous intraepithelial lesion (LSIL), abnormal squa-
mous cells of undetermined significance (ASC-US),
abnormal squamous cells cannot exclude HSIL (ASC-H),
or, high-grade squamous intraepithelial lesion (HSIL).
Breast invasive ductal carcinomas
Twenty-six FFPE IDC samples were selected at random
from Fletcher Allen Health Care Pathology (FAHC)
archives.
Vaginal intraepithelial neoplasia samples
114 FFPE VAIN samples were retrieved from FAHC
archives.
DNA extraction and quantification
DNA was extracted and purified from cultured SiHa and
C-33A cells and from cytology samples by proteinase K
digestion followed with a column clean-up method (Qia-
gen DNeasy Tissue Kit). DNA was extracted from FFPE tis-
sues by digesting five 6 µm dewaxed sections with
proteinase K as previously described [12]. DNA concentra-
tions were estimated using a DyNA Quant 200 Fluorome-
ter (Hoeffer Scientific).
Table 1: Details of the PCR protocols tested. All protocols included substitution of dTTP with dUTP and commenced with a uracil N-
glycosylase (UNG) incubation step (37°C for 30 minutes) followed by a HotStarTaq DNA Polymerase (Qiagen) activation/UNG 
inactivation step (95°C, 15 min).
Protocol Denaturation Touchdown annealing cycles Additional annealing cycles Extension Final extension
GP5+/GP6+ 1 min, 94°C - 2 min, 40°C (40–50 cycles) 1.5 min, 72°C 4 min, 72°C
TDP1 1 min, 94°C 2 min, 45°C to 40°C in 0.5°C 
decrements (11 cycles)
2 min, 40°C (29–39 cycles) 1.5 min, 72°C 4 min, 72°C
TDP2 1 min, 94°C 2 min, 50°C to 40°C in 1.0°C 
decrements (11 cycles)
2 min, 40°C (29–39 cycles) 1.5 min, 72°C 4 min, 72°C
TDP3 1 min, 94°C 2 min, 50°C to 40°C in 0.5°C 
decrements (21 cycles)
2 min, 40°C (19–29 cycles) 1.5 min, 72°C 4 min, 72°C
TDP4 1 min, 94°C 2 min, 55°C to 40°C in 1.0°C 
decrements (16 cycles)
2 min, 40°C (24–34 cycles) 1.5 min, 72°C 4 min, 72°CBMC Clinical Pathology 2005, 5:10 http://www.biomedcentral.com/1472-6890/5/10
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PCR protocols
The PCR protocols tested are summarized in Table 1. Ini-
tially, the standard GP5+/GP6+ assay cycling conditions
and four different touchdown protocols were compared.
In all protocols dTTP was substituted with dUTP (ACGU
dNTP mix [Sigma A5593]) and included a pre-PCR incu-
bation step with 'heat-killed'-Uracil N-Glycosylase (HK™-
UNG, Epicentre). HK™-UNG is a heat-labile form of UNG
that has maximal activity at 50°C and is designed to be
completely inactivated by 10 minute incubation at 65°C
(Epicentre technical note). Samples were incubated at
37°C for 30 min with 0.2U HK™-UNG according to sup-
plier's recommendations. A 'hot-start' step followed utiliz-
ing HotStarTaq DNA Polymerase (Qiagen), which
requires incubation at 95°C for 15 min to activate the
Taq. HotStarTaq was used at a concentration of 1U per 50
µl reaction. Magnesium chloride was included in reac-
tions at a concentration of 4 mM. Other reaction condi-
tions held constant for each protocol included 1X
HotStarTaq buffer [Tris-HCl (pH8.7), KCl, (NH4)2S04],
and each primer at a concentration of 1 µM, (GP5+ [5'-
TTTGTTACTGTGGTAGATACTAC-3'] and GP6+ [5'-
GAAAAATAAACTGTAAATCATATTC-3']). The Tm  of the
GP5+ primer is 45°C and the Tm of the GP6+ primer is
41°C, (Tm values are estimated for 50 mM salt conditions
and are calculated from the equation Tm= 59.9 + 41
[%GC] - [675/Primer Length]).
The standard GP5+/GP6+ amplification cycles comprise 1
min at 94°C, 2 min at 40°C, and 1.5 min at 72°C, with
the final extension step prolonged to 4 min to ensure
complete amplification of the 140–150 base pair products
[6,7]. The standard denaturation and extension tempera-
tures and times were retained in the four 'touchdown' pro-
tocols tested. The annealing period of 2 min was also
retained, as was the 'final' annealing temperature of 40°C.
Touchdown protocols (Table 1) with starting annealing
temperatures of 45°C, 50°C, or 55°C, decreasing by
0.5°C or 1.0°C decrements per PCR cycle down to 40°C
were evaluated. All PCR protocols were tried at 40 up to
Table 2: PCR protocol sensitivities for the detection of HPV-16 in SiHa/C-33A DNA mixtures. SiHa cell DNA (0.1 ng to 100 ng) was 
mixed with C-33A cell DNA to give final DNA quantities of 2 µg, 1 µg, 0.5 µg, or 0.1 µg. These preparations were tested with up to six 
different PCR protocols. HPV-16 detection was most successful using by the TDP3 and TDP4 conditions. Data are for protocols tested 
at 50 PCR cycles.   HPV detected,   HPV undetected, ND: not done.
Total DNA in PCR: 2 µg Total DNA in PCR: 1 µg
SiHa DNA 100 ng 25 ng 1 ng 0.5 ng 0.1 ng 100 ng 25 ng 1 ng 0.5 ng 0.1 ng
GP5+/6+
TDP1
TDP2
TDP3
TDP4 ND ND ND ND ND
MRT ND ND ND ND ND ND ND ND ND ND
Total DNA in PCR: 0.5 µg Total DNA in PCR: 0.1 µg
SiHa DNA 100 ng 25 ng 1 ng 0.5 ng 0.1 ng 100 ng 25 ng 1 ng 0.5 ng 0.1 ng
GP5+/6+
TDP1
TDP2
TDP3
TDP4
MRT ND ND ND ND ND
9 8
8 8 8 8 8 8 8 8 8 8
8 8 8 8 8 9 9 8 8 8
9 9 8 8 8 9 9 9 8 8
9 9 9 8 8 9 9 9 9 8
9 9 9 9 8
9 9 9 8 8 9 9 8 8 8
9 9 9 9 8 9 9 9 8 8
9 9 9 9 9 9 9 9 9 8
9 9 9 9 9 9 9 9 9 9
9 9 9 9 9 9 9 9 9 9
9 9 9 9 9BMC Clinical Pathology 2005, 5:10 http://www.biomedcentral.com/1472-6890/5/10
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50 cycles of amplification. Protocols were variously tested
with 5 ng up to 2 µg of DNA per 50 µl reaction. Experi-
ments were conducted using 0.2 ml PCR tubes (lightly
coated with mineral oil to enhance heat conduction) and
a Programmable Thermal Controller-100™ [PTC-100] (MJ
Research, Inc. MA).
Following completion of the study the authors became
aware of a GP5+/GP6+ protocol incorporating modified
ramping times (MRT) [13]. The MRT GP5+/GP6+ condi-
tions were tested on a subset of the samples. For the pur-
poses of this study, the protocol was modified to include
hot-start, dUTP, and 50 PCR cycles. Reaction ingredients
were as above. The MRT GP5+/GP6+ cycling conditions
were as follows:
HK™-UNG incubation step: 37°C 30 mins
Denaturation/HotStarTaq activation: 95°C 15 mins
Cycles (n = 50) 20 s at 94°C
In 24 s to 90°C
In 66 s to 48°C
In 30 s to 38°C
30 s at 38°C
In 18 s to 42°C
In 42 s to 71°C
80 s at 71°C
In 24 s to 69°C
In 90 s to 94°C
Final step: 4 min at 71°C
Detection of HPV-16 PCR product by agarose gel electrophoresis Figure 1
Detection of HPV-16 PCR product by agarose gel electrophoresis. SiHa cell DNA, 0, 0.1, 0.5, 1.0, 25, or 100 ng, was 
diluted in C-33A DNA to give a total of 0.5 µg or 0.1 µg DNA. The GP5+/GP6+, TDP1, TDP2, TDP3 and TDP4 assays were 
compared for the detection of HPV-16 product on an ethidium bromide (0.5 µg/ml) stained 2.5% agarose gel. RB: reagent 
blank, M: 50 base pair molecular weight ladder.
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Control measures
PCR
Negative control PCR was performed using C-33A cells
and reactions containing no template DNA. PCR amplifi-
cation of β-globin sequences was performed to confirm
sample fitness for PCR assay [14].
FFPE tissue-block sectioning
Measures to prevent potential cross-contamination of tis-
sue during sample sectioning, included wiping the micro-
tome blade with histoclear (xylene substitute) and 'DNA-
Erase' [ICN] (a DNA contamination removal reagent)
between blocks. Additionally, the first 10–20 sections cut
from a specimen were discarded prior to collecting sec-
tions for DNA extraction from the specimen.
HPV detection
Protocol sensitivity was measured by the presence of a
~150 base-pair band after 10 µl PCR product had been
sieved through a 2.5% agarose gel stained with 0.5 µg/ml
Table 3: PCR sensitivities for the detection of seven different HPV types. HPV recombinant plasmids were diluted in a background of 
100 ng C-33A DNA and amplified (50 cycles) by the GP5+/GP6+ protocol or by the TDP3 method.   HPV detected,   HPV 
undetected, Σm Total number of mismatches between the GP5+/GP6+ primers and the target HPV type.
GP5+/GP6+ TDP3
Σm HPV 1.5pg 150fg 15fg 1.5fg 150ag 15ag 1.5pg 150fg 15fg 1.5fg 150ag 15ag
21 6
33 3
34 5
43 1
45 6
75 2
10 51
9 8
9 9 9 9 9 8 9 9 9 9 9 9
9 9 8 8 8 8 9 9 9 8 8 8
9 9 9 9 8 8 9 9 9 9 9 9
9 9 9 8 8 8 9 9 8 8 8 8
9 9 8 8 8 8 9 9 9 8 8 8
8 8 8 8 8 8 9 9 9 8 8 8
9 9 8 8 8 8 9 9 9 9 9 8
Southern blot of TDP3 and MRT GP5+/GP6+ PCR products Figure 2
Southern blot of TDP3 and MRT GP5+/GP6+ PCR products. SiHa cell DNA, 0, 0.1, 0.5, 1.0, 25, or 100 ng, was diluted 
into a total of 0.1 µg DNA made up with C-33A DNA. After PCR with the TDP3 and MRT protocols and gel electrophoresis, 
products were electroblotted onto nylon membrane and hybridized with biotin-labeled HPV-16 oligonucleotide probe 
detected with streptavidin-alkaline phosphatase and NBT/BCIP. The data confirm the ~150 bp amplicons represent HPV 
sequences.
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ethidium bromide. Southern blot hybridization was per-
formed to test that the ~150 base-pair PCR product repre-
sented HPV DNA. HPV typing was performed by dot blot
hybridization of PCR products with up to 37 type-specific
biotin-labeled oligonucleotide probes. Biotin was
detected with streptavidin-alkaline phosphatase conju-
gate and the substrate nitrobluetetrazolium/5-bromo-4-
chloro-3-indolyl phosphate [12], or by sequencing.
Protocol reliability
Touchdown protocols were assessed on two or more occa-
sions on SiHa cell/C-33A DNA dilutions, and the TDP3
was also tested several times on recombinant HPV plas-
mid samples to determine data reproducibility. Clinical
samples (cytology, FFPE VAIN and breast tumors) were
tested once only with PCR protocols. Inter-laboratory tests
of different PCR assays were not performed.
Results
Detection of HPV in SiHa cells
The ability of the protocols to amplify HPV-16 from 100
ng, 25 ng, 1 ng, 0.5 ng or 0.1 ng of SiHa cell DNA 'hidden'
in a total quantity of either 2 µg, 1 µg, 500 ng or 100 ng
DNA (made up with C-33A DNA) was examined. The
results are summarized in Table 2, and Figure 1. Each
touchdown protocol improved the detection of HPV
sequences. The best protocols were the TDP3 and TDP4
that demonstrated HPV-16 amplification from 0.1 ng of
SiHa cell DNA in a total DNA content of 100 ng or 500 ng
(Figure 1). When the total DNA content was 1 µg, these
protocols enabled successful HPV-16 amplification from
0.5 ng of SiHa DNA (Table 2). HPV-16 was amplifiable by
the TDP3 protocol from 1 ng of SiHa cell DNA when the
total reaction DNA was 2 µg (Table 2). The least successful
protocol was the standard GP5+/GP6+ that did not
amplify HPV-16 from SiHa cell DNA diluted in 1 µg or 2
µg of background DNA and was only able to demonstrate
HPV-16 from 1 ng of SiHa cell DNA contained in a total
of 500 ng DNA (Table 2, Figure 1). Data was confirmed by
repeat PCR tests. The MRT GP5+/GP6+ protocol was also
tested on SiHa cell DNA diluted in a background of 100
ng C-33A DNA and supported detection of HPV-16 from
0.1 ng SiHa cell DNA. Figure 2 details a Southern blot of
PCR products from the TDP3 and MRT protocols hybrid-
ized with a biotin-labeled HPV-16 oligonucleotide probe.
Detection of HPV recombinant plasmid DNA
The ability of the standard GP5+/GP6+ and TDP3 proto-
cols (50 cycles each) to amplify 15ag, 150ag, 1.5fg, 15fg,
150fg, or 1.5pg of HPV-16, 31, 33, 45, 51, 52, or, 56 plas-
mid in a background of C-33A cell DNA (to a total of 100
ng DNA per PCR) was examined. The same set of 'master
dilutions' were used in the two different PCR assays. The
results are shown in Figures 3 and 4, and Table 3. With the
TDP3 protocol HPV-16 amplification product was
observed from (all three) 15ag recombinant plasmid dilu-
Detection of recombinant HPV plasmid by GP5+/GP6+ PCR Figure 3
Detection of recombinant HPV plasmid by GP5+/GP6+ PCR. HPV (types 16, 31, 33, 45, 51, 52, and 56) recombinant 
plasmids, 0, 15ag, 150ag, 1.5fg, 15fg, 150fg, 1.5pg, were diluted in 100 ng C-33A DNA and amplified (50 cycles) using the GP5+/
GP6+ protocol. Positive control amplification of HPV-18 from 100 ng HeLa cell DNA is also shown.
HPV-16
HPV-33
HPV-51
HPV-56
HPV-31
HPV-45
HPV-52
HPV
plasmid
DNA:
00015 15 15 150 1.5 15 150 1.5
0 0 0 ag ag ag ag fg fg fg pg
00015 15 15 150 1.5 15 150 1.5
0 0 0 a ga g a ga g f gf g f g p g
100ng Total DNA 100ng Total DNA
HeLa
150bp
150bp
150bp
150bp 150bp
150bp
150bp
150bpBMC Clinical Pathology 2005, 5:10 http://www.biomedcentral.com/1472-6890/5/10
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tions, and HPV-45 from one of three 15ag HPV DNA dilu-
tions. HPV-51 was detectable following amplification
from 150ag DNA template; HPV-33, 52, and 56 from 15fg
template; and, HPV-31 from 150fg recombinant HPV
DNA. With the GP5+/GP6+ protocol HPV-16 was ampli-
fiable from 150ag recombinant plasmid; HPV-45 from
1.5 g template; HPV-31 from 15fg; and HPV-33, 51, and
56 from 150fg template; HPV-52 was not detected. Data
were confirmed up on repeat PCR.
Detection of multiple HPV types
To examine how a touchdown protocol affected the detec-
tion of multiple HPV types, dilutions of HPV-16, 45, 51,
and 52 were combined in a background of 100 ng C-33A
DNA. Five mixtures were compared: 1.5pg each HPV type
combined in a PCR, 150fg of each type in a PCR, 15fg of
each type in a PCR, 1.5fg of each type in a PCR, or 150ag
of each type in a PCR. Following amplification using the
TDP3 protocol, duplicate rows of 0.6 µl heat-denatured
product was dot-blot hybridized with type-specific
probes. The results are shown in Figure 5. HPV-16 was
detectable following amplification of each dilution mix-
ture. HPV types 45, 51, and 52 were detectable following
amplification of mixtures containing 1.5pg, 150fg, 15fg,
or 1.5fg, but not 150ag HPV DNA. Repeat PCR tests were
not performed.
Detection of HPV in cytology samples
In a previous study [15], GP5+/GP6+ PCR was used to
determine HPV type and prevalence amongst a set of
abnormal cytology samples and 290/355 (82%) were
recorded as HPV positive. The TDP3 and TDP4 protocols
were tested on 100 ng and 500 ng of DNA from samples
that had tested HPV negative. Both protocols detected
HPV in samples previously recorded as HPV negative,
with the TDP3 representing a more efficient assay (Figure
6). In some instances, HPV sequences were only detecta-
ble when 100 ng of DNA was included in the PCR, and
samples were apparently HPV negative when 1.0 µg or
500 ng of sample DNA was used in an assay (Figure 7). All
65 abnormal cytology samples previously recorded as
HPV negative were repeated with 50 cycles of the TDP3
protocol using 100 ng of sample DNA as template and 47
(72%) samples were recorded as HPV positive. Seventeen
Detection of recombinant HPV plasmid by TDP3 PCR Figure 4
Detection of recombinant HPV plasmid by TDP3 PCR. HPV (types 16, 31, 33, 45, 51, 52, and 56) recombinant plas-
mids, 0, 15ag, 150ag, 1.5fg, 15fg, 150fg, 1.5pg, were diluted in 100 ng C-33A DNA and amplified (50 cycles) using the TDP3 con-
ditions.
HPV-16
HPV-33
HPV-51
HPV-56
HPV-31
HPV-45
HPV-52
HPV
plasmid
DNA:
00015 15 15 150 1.5 15 150 1.5
0 0 0 ag ag ag ag fg fg fg pg
00015 15 15 150 1.5 15 150 1.5
000a g a g a g a gf g f gf g p g
100ng Total DNA 100ng Total DNA
150bp
150bp
150bp
150bp
150bp
150bp
150bpBMC Clinical Pathology 2005, 5:10 http://www.biomedcentral.com/1472-6890/5/10
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HPV types (6, 11, 16, 18, 31, 33, 35, 40, 42, 52, 58, 66, 67,
73, 81 [CP8304], 84 [MM8], and cand91 [CP6108]) were
detected amongst these 47 samples. Multiple infections
were recorded in 9/47 (19%) samples.
Fifty-four of the 65 'HPV negative' samples were also
tested with the MRT protocol. Of these 54 samples, 10
were HPV negative and 44 HPV positive with the TDP3
protocol. Of the 10 negative samples, 1 tested HPV-53
positive by the MRT method, and of the 44 positive sam-
ples, 16 (36%) were negative with the MRT method. Five
HPV types (16, 18, 31, 35, and 81) went undetected by the
MRT method in this sample. An additional 25 samples
that were negative following primary screening by the
TDP3 assay were identified; none tested HPV positive after
PCR with the standard GP5+/GP6+ protocol (50 PCR
cycles). Two of the 25 samples tested positive (for HPV-
39, and for HPV-51) by the MRT protocol. Thus, of 44
samples negative with the standard GP5+/GP6+ assay, 44
(100%) tested positive with the TDP3 protocol, and 28
(64%) tested positive with the MRT conditions; and, of 35
samples negative by the standard GP5+/GP6+ assay and
the TDP3 assay, 3 (8.6%) tested positive with the MRT
protocol.
The TDP3 protocol has subsequently been tested on 799
abnormal cytological samples and 752 (94%) have tested
positive for one or other of 37 types: HPV-6, 11, 16, 18,
31, 32, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 54, 55, 56,
58, 59, 61, 62, 66, 67, 69, 70, 72, 73, 81, 82, 83, 84, 87,
cand89, cand90, and cand91.
Detection of HPV in FFPE VAIN samples
The GP5+/GP6+ and TDP3 protocols (both 50 cycles)
were compared for the detection of HPV in 5 ng, 20 ng, 50
ng and 100 ng of DNA extracted from six VAIN lesions
(Figure 8). HPV sequences were detectable by TDP3 assay
in all six samples at each sample DNA quantity. The
GP5+/6+ assay detected HPV in all six cases, but electro-
phoretic band strength was strong only with 100 ng DNA
in the PCR and tended to be weaker or absent at other
template DNA quantities (Figure 8). Subsequent analysis
(using the TDP3 conditions) of VAIN lesions from 114
patients demonstrated HPV in 111 (97.4%) samples.
Twenty-one HPV types were identified: HPV types 6, 11,
16, 18, 31, 33, 35, 40, 42, 43, 45, 51, 54, 56, 58, 59, 73,
81, 83, 84, and cand90. Double or multiple infections
were detected in 19 (13%) samples.
Detection of HPV in FFPE breast invasive ductal carcinoma 
samples
A preliminary assay of 26 IDC samples (arbitrary 10 µl of
DNA extract) by GP5+/GP6+ PCR demonstrated faint
bands upon electrophoresis for five (19%) samples. Fol-
lowing DNA quantification, one of these samples was
Dot blot hybridization detection of multiple HPV types after  TDP3 PCR Figure 5
Dot blot hybridization detection of multiple HPV 
types after TDP3 PCR. HPV types 16, 45, 51, and 52 were 
combined (1.5pg, 150fg, 15fg, 1.5fg, or 150ag of each type) in 
a background of 100 ng C-33A DNA. After PCR, 0.6 µl of 
denatured product was spotted onto nylon membrane and 
hybridized with biotin-labeled HPV type specific oligonucle-
otide probe. Duplicate dot preparations were prepared.
HPV-16
HPV-45
HPV-51
HPV-52
1.5pg 150fg 15fg 1.5fg 150agBMC Clinical Pathology 2005, 5:10 http://www.biomedcentral.com/1472-6890/5/10
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compared for detection of HPV by GP5+/GP6+ assay and
TDP3 assay (both for 50 cycles), using 20 ng, 100 ng, 225
ng, 325 ng or 450 ng of DNA extract in the PCR (Figure 9).
A weak band was obtained using the GP5+/GP6+ assay
following amplification from 225 ng DNA template but
HPV was not detected at any of the other sample concen-
trations. Bands were clearly visible using the TDP3 assay
from 100 ng, 225 ng and 325 ng sample quantities. There
is a faint band after amplification from 20 ng, but ampli-
fication is not evident for 450 ng sample DNA. The TDP3
assay was subsequently applied to the other 25 breast
tumor samples (~200 ng sample DNA in the PCR) and
HPV was detected in another 14 instances (Figure 10).
Overall 15/26 (58%) breast tumors tested positive by this
assay for HPV. Dot blot hybridization demonstrated four-
teen samples were positive for HPV-16 and one for HPV-
31.
Discussion
The main finding of this study is that touchdown general
primer PCR coupled with control of the quantity of sam-
ple DNA in a PCR supports the detection of low-copy
number HPV in an excess background of human DNA
sequences. A high percentage of abnormal cervical cyto-
logical samples previously recorded as HPV negative
tested HPV positive by this approach. It has also been
demonstrated that a wide range of HPV types and multi-
ple infections are detectable using a touchdown protocol.
Detection of minority HPV DNA
The potential of PCR to detect minority nucleic acid spe-
cies is the genius of the technique. However, the presence
of background DNA may compromise PCR efficiency by
giving rise to non-specific primer annealing [16]. Assays
such as the GP5+/GP6+ use one pair of primers to amplify
a wide range of HPV types and necessarily each primer
contains varying numbers of mismatches relative to any
given HPV type [17]. Low-stringency primer-annealing
conditions were originally defined for the GP5+/GP6+
assay [7] however, these conditions permit GP5+/GP6+
primer annealing to human sequences [6].
In this study a hot start step was introduced to prevent
annealing that can occur at PCR set-up between primers
and single-stranded DNA sequences produced during
DNA extraction [9,16]. Four touchdown protocols were
tested to assess how a touchdown annealing approach
affects the amplification of HPV sequences. In the first
instance, these protocols were tested on a model system
consisting of small quantities of SiHa cell DNA 'hidden' in
varying amounts of C-33A cell DNA.
The SiHa cell line is known to contain approximately one
slightly truncated copy of the HPV-16 genome integrated
in chromosome 13q21-31 [11]. The cell line is hyper-dip-
loid but has been shown to be disomic with respect to
chromosome 13 [11]. It is possible to approximate the
number of copies of HPV-16 detected by the various pro-
tocols tested assuming for the purpose of the approxima-
tion that there are 6.6 × 109 DNA base pairs per SiHa cell.
One base pair weighs 650 daltons and one dalton weighs
1.66 × 10-24g. Therefore, one diploid cell contains 7.12pg
of DNA, and there will be one copy of the GP5+/GP6+
primer target per 3.56pg of SiHa cell DNA extract. It fol-
lows that the number of copies of HPV-16 in 0.1 ng of
SiHa cell DNA will be ~28; in 0.5 ng SiHa DNA there will
Amplification of HPV from abnormal cervical cell DNA samples by TDP3 and TDP4 Figure 6
Amplification of HPV from abnormal cervical cell DNA samples by TDP3 and TDP4. Seven samples that tested 
negative for HPV using standard GP5+/GP6+ cycling conditions were assessed with the TDP3 and TDP4 assays. Both TDP3 
and TDP4 supported the detection of HPV in sample 4 when 100 ng DNA was subject to PCR but not when 500 ng DNA was 
in a reaction. HPV was detected in sample 2 by the TDP3 protocol with 100 ng or 500 ng template DNA and by the TDP4 pro-
tocol at 500 ng but not 100 ng of sample. RB: reagent blank.
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be ~140 copies; in 1 ng ~280 copies; in 25 ng ~7000 cop-
ies and in 100 ng ~28,000. HPV-16 was amplifiable from
smaller quantities of SiHa cell DNA as the total quantity
of DNA reduced from 2 µg to 500 ng for all protocols. Two
touchdown protocols (TDP3, TDP4) were routinely able
to detect 0.1 ng SiHa HPV DNA (~28 copies) in a total
DNA quantity of 500 ng (approximately equal to DNA
extracted from 70,000 cells [i.e. 1 copy HPV-16 detected
per 2500 cells]). In contrast, the best performance of the
GP5+/GP6+ protocol was the demonstration of HPV-16
from 1 ng of SiHa cell DNA (~280 HPV-16 copies) in a
background of 500 ng total DNA. Unlike TDP3 and TDP4
protocols, the standard GP5+/GP6+ assay failed to dem-
onstrate HPV when the total DNA content in a reaction
was 1 µg or 2 µg. It is noticeable from Figure 1 that some
of the protocols gave slightly more intense bands, ~150
bp in size, following amplification of HPV-16 sequences
in a background of 500 ng DNA compared to the amplifi-
cation in a background of 100 ng. This empirical finding
was reproducible on repeat PCR. This observation is coun-
ter-intuitive; however, given the nature of the touchdown
approach to annealing, the character of the dilutions, and
the high number of PCR cycles, the PCR assays tested are
essentially qualitative rather than quantitative.
The significantly improved detection of low-copy HPV-16
by touchdown protocols illustrates the important influ-
ence background DNA can have on detection sensitivity.
The findings are particular noteworthy given that relative
to the target HPV-16 sequence, the GP5+ primer sequence
(Tm = 45°C) has just two mismatches and the GP6+
primer (Tm = 41°C) has no mismatches. The data show
that under low-stringency annealing conditions and when
the target is low-copy HPV, considerable non-specific
primer annealing with human sequences must occur
despite the near perfect homology of the primers for the
HPV-16 L1 open reading frame target.
The MRT GP5+/GP6+ protocol was also found to detect
low-copy HPV in a background of human sequences. This
assay incorporates periods of slow temperature changes
from the denaturation step to the annealing step and from
the annealing step to the extension step. This approach
may allow for better specific annealing of primers with
HPV target during the gradual cooling to the final anneal-
ing temperature of 38°C than is possible with the stand-
ard conditions. Possibly, the express heating/cooling
default settings of current generation thermal cyclers may
HPV detection in six VAIN lesions by GP5+/GP6+ and TDP3 assays Figure 8
HPV detection in six VAIN lesions by GP5+/GP6+ and TDP3 assays. Sample DNA in PCR: 100 ng, 50 ng, 20 ng, or 5 
ng. M: 50 bp molecular weight marker, RB: reagent blank.
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Detection of HPV by TDP3 in abnormal cervical cell samples Figure 7
Detection of HPV by TDP3 in abnormal cervical cell 
samples. Samples had previously tested negative for HPV 
using standard GP5+/GP6+ cycling conditions. HPV detec-
tion was dependent on the total amount of DNA included in 
the PCR.
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compromise the efficiency of the GP5+/GP6+ PCR assay
as developed using early generation machines [6,7].
Detection of HPV recombinant plasmid DNA
To examine the effect of a touchdown protocol on a wider
range of HPV types, recombinant HPV/plasmid DNA sam-
ples were diluted in C-33A DNA and tested with the TDP3
protocol. There are three primer mismatches with respect
to HPV-33, one in the GP5+ primer and two in the GP6+
primer. For HPV-45 there are three mismatches that are all
in the GP5+ primer sequence. HPV-31 and 56 each have
one mismatch in the GP5+ primer and three in the GP6+
primer. For HPV-52 there are seven mismatches, includ-
ing five in the GP5+ primer. HPV-51 has the greatest
number of mismatches of any HPV type amplified by the
GP5+/6+ system: six mismatches in the GP5+ primer and
four in the GP6+ primer. Not surprisingly, HPV-16 was
the most efficiently amplified type (Figure 3). Amplifica-
tion product was detectable from 15ag DNA (approxi-
mately equivalent to 1 copy of the recombinant HPV
plasmid) in a background of 100 ng human DNA (equiv-
alent to 14,000 cells). HPV-45 and 51 were amplifiable
from 150ag (10 HPV/plasmid copies); types 33, 52, and
56 from 15fg (100 copies of HPV) DNA; and, HPV-31
from 150fg (1000 copies) of recombinant DNA. Clearly,
for such small quantities of DNA, slight variations in
pipetting accuracy and/or DNA concentration estimate
might alter the final sensitivity data. Nonetheless, the data
indicates firstly that a touchdown protocol can sensitively
amplify a range of HPV types, and secondly that the effi-
ciency of amplification may not be a simple function of
the number of mismatches between the primer and target
sequence. With the TDP3 protocol HPV-31 (4 mis-
matches) was less efficiently amplified than HPV-56 (4
mismatches), HPV-52 (7 mismatches), or HPV-51 (10
mismatches) (Figure 4, Table 3). The TDP3 amplified six
of the seven HPV types tested with greater sensitivity than
the standard GP5+/GP6+ conditions. HPV-31 was detect-
able as a faint band from 15fg template DNA following
the standard PCR, whereas the detection limit with the
TDP3 protocol was 150fg (Figures 3 and 4, Table 3). HPV-
52 was not detectable by the standard protocol at the dilu-
tion range tested but was detectable from 15fg starting
template using the TDP3 protocol. These data again indi-
cate that the detection efficiency for different HPV types
by a general primer method may not follow easily predict-
able rules. General primer annealing involves a dynamic
inter-relationship depending on HPV copy number,
primer affinity for different HPV types, human sequence
concentration, and, primer affinity for human sequences
at a given annealing temperature. The empirical data indi-
cate that a touchdown annealing approach helps negoti-
ate these variables to support sensitive detection of a wide
range of HPV types.
Detection of multiple HPV types
This study also examined the ability of a touchdown pro-
tocol to amplify HPV types-16 (2 mismatches), 45 (3 mis-
Demonstration of HPV in FFPE breast invasive ductal carcinomas following TDP3 amplification Figure 10
Demonstration of HPV in FFPE breast invasive ductal carcinomas following TDP3 amplification. 200 ng of sam-
ple DNA were subject to a total of 50 PCR cycles. Samples 1, 2, 3, 6, 7, 8, 9, 10, 11, 15, 16, 20, 21 and 25 were recorded as 
HPV positive following electrophoresis and dot blot hybridization. M: 50 bp molecular weight marker, RB: reagent blank.
M RB 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
150bp
Comparison of GP5+/GP6+ and TDP3 amplification of HPV  sequences from a FFPE breast invasive ductal carcinoma Figure 9
Comparison of GP5+/GP6+ and TDP3 amplification 
of HPV sequences from a FFPE breast invasive ductal 
carcinoma. Sample DNA in PCR, A: 450 ng, B: 325 ng, C: 
225 ng, D: 100 ng, E: 20 ng. The TDP3 assay facilitated detec-
tion of HPV in 100 ng, 225 ng and 325 ng sample, whereas 
with GP5+/6+ assay conditions a HPV was detectable (weak 
band) only when 225 ng sample was in the PCR. 50 cycles of 
PCR were used with each of the protocols. RB: reagent 
blank.
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matches), 51 (10 mismatches), and, 52 (7 mismatches)
combined in one PCR (Figure 5). Again, HPV-16 was
detected with the highest sensitivity; however, the other
three types were identifiable following dot blot hybridiza-
tion demonstrating that the touchdown protocol did not
favor HPV-16 amplification to the exclusion of other
types. An exhaustive assessment of the effect of different
concentrations of HPV types within a PCR on the detec-
tion of multiple types was beyond the resources available
for this study.
Detection of HPV in cervical smear samples
An excess of background human DNA is likely to be a
common situation when performing PCR on DNA
extracted from routine cervical smear samples. The extent
to which normal or lesion tissues are scraped from the cer-
vix cannot be controlled. For efficient HPV PCR amplifica-
tion, the study data strongly support the use of
standardized quantities of DNA and not regular volumes
containing arbitrary amounts of DNA. Overall, the cell
line and clinical sample studies indicate that in a 50 µl
reaction, between 100 ng and 200 ng sample DNA sup-
ports the most efficient PCR. Using optimized amounts of
DNA, the TDP3 protocol demonstrated one or other of
seventeen different HPV types in 47 of 65 (72%) abnor-
mal cytology samples HPV negative by the regular GP5+/
GP6+ protocol. Multiple infections were found in 9/47
(19%) of the samples.
The MRT GP5+/GP6+ conditions were tested on 54 of the
65 GP5+/GP6+ negative samples. Twenty-eight (64%) of
44 samples positive by the TDP3 were also positive by the
MRT protocol, and 1 of 10 samples negative by the TDP3
protocol was positive by the MRT. Of an additional 25
abnormal cytological samples negative for HPV by the
TDP3 assay, none tested positive with the standard GP5+/
GP6+ method, but two samples were positive by the MRT
protocol. Again, these data show that HPV detection can
be highly dependent on assay conditions and also dem-
onstrate that two or more methods may be required for
inclusive HPV screening. Nevertheless, the above compar-
ison of methods together with the demonstration of HPV
in 94% of 799 abnormal cytological samples indicates a
touchdown approach supports wide-ranging and sensitive
HPV detection.
Detection of HPV in FFPE samples
This study also examined the effect of touchdown PCR
and sample DNA quantity on the amplification of HPV
from FFPE tissues, where DNA quality is likely to be poor.
VAIN lesions were chosen as an example of tissues from
which HPV virions are actively shed and therefore where
HPV DNA is in a relative abundance [18]. Amplification
of HPV from VAIN lesions was readily accomplished by
both the GP5+/GP6+ and TDP3 protocols although the
TDP3 assay was able to amplify HPV from smaller quan-
tities of template DNA than the GP5+/GP6+ assay (Figure
8). The data again illustrates the effect of DNA content on
amplification efficiency. Assay of 114 VAIN lesions by
TDP3 has demonstrated 21 different HPV types in 111
HPV positive samples, with double or multiple infections
in 17 (15%) of the samples, again suggesting that a touch-
down approach sensitively detects a wide range of HPV
types.
Breast carcinomas were chosen for study as an example of
a tumor where there are widely differing estimates of HPV
prevalence. Most early studies of breast tumors found no
evidence of HPV following PCR assay [5,19-21]. However,
other investigations (by Southern blot hybridization, and
by PCR) have reported high-risk HPV types (e.g. HPV-16,
18, or 33) in 24/50 (48%), 5/17 (30%), 19/41 (46%), 14/
32 (44%), and 6/17 (35%) breast carcinomas [4,22-25].
de Villiers et al. PCR tested paired breast carcinoma and
nipple tissues from 29 patients for anogenital and skin
HPV types. HPV was detected in 25/29 (86%) carcinomas
and in 20/29 (69%) nipple tissues [26]. In the present
study, application of the GP5+/GP6+ assay using an arbi-
trary DNA quantity in the PCR indicated 5/26 (19%) inva-
sive ductal carcinomas were HPV positive. Subsequent
assays using the TDP3 protocol and 200 ng of sample
indicated 15/26 (58%) tumors were HPV positive. These
data add to the evidence that HPV sequences are present
in breast tumor tissues. However, that HPV was detectable
in most tumors only after use of a highly optimized PCR
protocol may indicate that HPV is in a latent form and/or
is confined to a subset of tumor cells or other cells associ-
ated with a tumor mass. Perhaps there may be parallels
with Epstein Barr Virus (EBV) detection in breast tumors.
EBV has been reported in up to 51% of breast carcinomas
by sensitive PCR assay [27], but it has since been sug-
gested the EBV detected is amplified from EBV positive
tumor infiltrating lymphocytes and not from tumor cells
per se [28]. Further studies are required to determine
whether HPV detected in breast tumors represents an inci-
dental 'passenger' or has causal significance. Additionally,
given the disparate estimates of HPV prevalence in breast
tumors, future studies might incorporate more rigorous
control measures such as cutting sections of HPV negative
tissues for DNA extraction and PCR in between successive
breast tumor specimens to test for cross-contamination
with HPV positive samples.
Carry-over contamination control
In this study dTTP was replaced with dUTP in all protocols
in order to identify a sensitive PCR test that also includes
a control measure against carry-over contamination.
However, uracil N-glycosylase (UNG) is an enzyme that
has a degree of thermostability and may also become reac-
tivated after completion of a PCR protocol [29,30]. HK™-BMC Clinical Pathology 2005, 5:10 http://www.biomedcentral.com/1472-6890/5/10
Page 13 of 14
(page number not for citation purposes)
UNG (Epicentre) is designed to be heat-labile and free of
such shortcomings, but it has been reported that even
heat-labile forms of UNG may retain some residual activ-
ity and spoil PCR efficiency [29]. Further, dUTP is less effi-
ciently incorporated into PCR amplicons than dTTP [30].
UNG/dUTP usage might therefore result in suboptimal
PCR assay performance and even greater sensitivity for
HPV might be possible for all the protocols tested using
regular dNTPs.
Clinical utility
The impetus for this study was to determine whether
abnormal cytological samples that tested HPV negative by
a commonly used PCR assay were in fact HPV positive.
Using a touchdown protocol, HPV has been demon-
strated in a high percentage of samples previously
recorded as HPV negative consistent with HPV represent-
ing a necessary cause of most (if not all) abnormal cervical
cytological conditions. However, an assay with high ana-
lytical sensitivity for HPV might not be appropriate as a
clinical test. The HPV status of cytological samples has
been proposed as a marker to identify patients with
underlying high-grade cervical intraepithelial neoplasia
(CIN) [31] and current clinically approved HPV tests
detect the bulk of high-grade CIN and invasive cervical
carcinoma. Increased sensitivity for HPV might lead to
reduced test specificity for high-grade CIN.
Conclusion
This study has demonstrated that a touchdown modifica-
tion of the GP5+/GP6+ assay coupled with attention to
the quantity of DNA in a PCR significantly improves the
detection of low-copy HPV DNA without compromising
the ability of the technique to detect a wide range of HPV
types or multiple infections. A touchdown approach may
be especially beneficial as an analytical test for the re-eval-
uation of (apparently) HPV negative abnormal cervical
cytological or histological samples and for investigating
the association of HPV with non-anogenital lesions and
tumors. Further studies are required to determine the clin-
ical utility of a touchdown PCR approach to HPV detec-
tion and to compare the performance with recently
developed (highly sensitive) multi-primer HPV PCR
assays such as the PGMY [32] and the SPF10 [33].
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